BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28287184)

  • 1. A 'Disease Severity Index' to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia.
    Ferreira D; Falahati F; Linden C; Buckley RF; Ellis KA; Savage G; Villemagne VL; Rowe CC; Ames D; Simmons A; Westman E
    Sci Rep; 2017 Mar; 7():44368. PubMed ID: 28287184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.
    Falahati F; Ferreira D; Muehlboeck JS; Eriksdotter M; Simmons A; Wahlund LO; Westman E
    Neuroimage Clin; 2017; 16():418-428. PubMed ID: 28879083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.
    Rowe CC; Bourgeat P; Ellis KA; Brown B; Lim YY; Mulligan R; Jones G; Maruff P; Woodward M; Price R; Robins P; Tochon-Danguy H; O'Keefe G; Pike KE; Yates P; Szoeke C; Salvado O; Macaulay SL; O'Meara T; Head R; Cobiac L; Savage G; Martins R; Masters CL; Ames D; Villemagne VL
    Ann Neurol; 2013 Dec; 74(6):905-13. PubMed ID: 24448836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.
    Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
    J Korean Med Sci; 2016 Feb; 31(2):286-95. PubMed ID: 26839485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual role of cognitive reserve in subjective cognitive decline and mild cognitive impairment: a 7-year follow-up study.
    Mazzeo S; Padiglioni S; Bagnoli S; Bracco L; Nacmias B; Sorbi S; Bessi V
    J Neurol; 2019 Feb; 266(2):487-497. PubMed ID: 30604054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study.
    Son SJ; Lee KS; Lee Y; Baek JH; Choi SH; Na DL; Seo SW; Oh BH; Hong CH
    J Clin Psychiatry; 2012 Dec; 73(12):1555-62. PubMed ID: 23146133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly.
    Dhilla Albers A; Asafu-Adjei J; Delaney MK; Kelly KE; Gomez-Isla T; Blacker D; Johnson KA; Sperling RA; Hyman BT; Betensky RA; Hastings L; Albers MW
    Ann Neurol; 2016 Dec; 80(6):846-857. PubMed ID: 27696605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
    Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
    Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment.
    Alegret M; Cuberas-Borrós G; Espinosa A; Valero S; Hernández I; Ruíz A; Becker JT; Rosende-Roca M; Mauleón A; Sotolongo O; Castell-Conesa J; Roca I; Tárraga L; Boada M
    J Alzheimers Dis; 2014; 41(3):739-48. PubMed ID: 24685632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large intracranial volume accelerates conversion to dementia in males and APOE4 non-carriers with mild cognitive impairment.
    An H; Son SJ; Cho S; Cho EY; Choi B; Kim SY;
    Int Psychogeriatr; 2016 May; 28(5):769-78. PubMed ID: 26674540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated progression from mild cognitive impairment to dementia among APOE ε4ε4 carriers.
    Xu WL; Caracciolo B; Wang HX; Santoni G; Winblad B; Fratiglioni L
    J Alzheimers Dis; 2013; 33(2):507-15. PubMed ID: 23247007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology.
    Ramakers IH; Visser PJ; Aalten P; Bekers O; Sleegers K; van Broeckhoven CL; Jolles J; Verhey FR
    Dement Geriatr Cogn Disord; 2008; 26(2):101-8. PubMed ID: 18617739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain atrophy rates in first degree relatives at risk for Alzheimer's.
    Lampert EJ; Roy Choudhury K; Hostage CA; Rathakrishnan B; Weiner M; Petrella JR; Doraiswamy PM;
    Neuroimage Clin; 2014; 6():340-6. PubMed ID: 25379448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.
    Kerr DS; Stella F; Radanovic M; Aprahamian I; Bertollucci PH; Forlenza OV
    Bipolar Disord; 2016 Feb; 18(1):71-7. PubMed ID: 26877211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations.
    Orellana C; Ferreira D; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Lovestone S; Simmons A; Wahlund LO; Westman E;
    Neurodegener Dis; 2016; 16(1-2):77-86. PubMed ID: 26726737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
    Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
    EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.